Status:

COMPLETED

ECG-I Phenotyping of Persistent AF Based on Driver Distribution to Predict Response to Pulmonary Vein Isolation

Lead Sponsor:

Barts & The London NHS Trust

Conditions:

Atrial Fibrillation

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

Atrial fibrillation (AF) is an irregular heart rhythm associated with significant morbidity and mortality. The pulmonary veins (the blood vessels carrying blood from the lungs into the left atrium) ha...

Detailed Description

Atrial Fibrillation (AF) is the commonest heart rhythm disturbance and is associated with significant morbidity and mortality. Catheter ablation (CA) is a procedure where catheters (leads) are passed ...

Eligibility Criteria

Inclusion

  • Patients diagnosed with Persistent AF (i.e. episodes of AF that are continuous for \> 1 week or have required DC cardioversion)
  • Willing for ablation.
  • Age between 18 to 80.
  • left atrial diameter \<5 cm
  • left ventricular function \>40%.
  • New York Heart Association class \< 3.

Exclusion

  • Persistent AF diagnosed \> 2 years ago
  • left atrial diameter \> 5 cm
  • Severe left ventricular impairment (EF \< 40%)
  • New York Heart Association class 3 or 4 heart failure
  • Known hypertrophic cardiomyopathy, cardiac sarcoid, or arrythmogenic ventricular cardiomyopathy.
  • Known inherited arrhythmia such as Brugada or long QT syndromes
  • Valvular disease that is more than moderate
  • History of valve replacement (metallic or tissue)
  • History of congenital heart disease (other than patent foramen ovale)
  • Previous left atrial ablation (percutaneous or surgical)
  • Cardiac surgery or percutaneous coronary intervention within the last 3 months.
  • Myocardial infarction or unstable angina within the last 3 months.
  • Unwillingness for ablation
  • Unwillingness to be involved in study
  • Suspected reversible cause of AF
  • Any other contraindication to catheter ablation
  • Age \< 18 yrs or \> 80 years
  • Pregnancy
  • Morbid obesity (defined as BMI \>40)
  • Any other medical problem likely to cause death within the next 18 months

Key Trial Info

Start Date :

January 8 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 31 2021

Estimated Enrollment :

140 Patients enrolled

Trial Details

Trial ID

NCT03394404

Start Date

January 8 2018

End Date

March 31 2021

Last Update

October 22 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Barts Heart Centre

London, United Kingdom, EC1A 7BE